---
document_datetime: 2025-12-29 11:34:46
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tezspire.html
document_name: tezspire.html
version: success
processing_time: 0.116027
conversion_datetime: 2025-12-30 03:16:58.899502
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tezspire

[RSS](/en/individual-human-medicine.xml/67609)

##### Authorised

This medicine is authorised for use in the European Union

tezepelumab Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tezspire](#news-on)
- [More information on Tezspire](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Tezspire is a medicine used to treat:

- severe asthma in adults and adolescents (12 years of age and older). It is used as an additional treatment in adults and adolescents with severe asthma that is not adequately controlled by a combination of high-dose corticosteroids taken by inhalation plus another asthma medicine;

- severe chronic (long-term) rhinosinusitis with nasal polyps (inflamed lining of the nose and sinuses with growths in the nose) in adults. Tezspire is used with a corticosteroid given into the nose when treatment with a corticosteroid given by mouth or injection and/or surgery, does not work well enough.

Tezspire contains the active substance tezepelumab.

Expand section

Collapse section

## How is Tezspire used?

Tezspire can only be obtained with a prescription, and treatment should be initiated by a doctor with experience in diagnosing and treating the conditions that Tezspire is used to treat.

Tezspire is injected under the skin every 4 weeks. This medicine is used for long-term treatment. Every year the doctor will decide whether to continue treatment, based on how well the patient's condition is controlled.

The patient or their caregiver may inject the medicine themselves after they have received training.

Tezspire should not be used to treat asthma attacks. Patients should contact their doctor if their asthma remains uncontrolled or worsens after starting this medicine.

For more information about using Tezspire, see the package leaflet or contact your doctor or pharmacist.

## How does Tezspire work?

In patients with asthma and chronic rhinosinusitis with nasal polyps, a protein called thymic stromal lymphopoietin (TSLP) plays a role in the immune response that causes inflammation in the airways. The active substance in Tezspire, tezepelumab, is an antibody (a type of protein) that prevents TSLP from attaching to its receptor (target). This reduces inflammation in the airways and the lining of the nose and sinuses which improves disease symptoms.

## What benefits of Tezspire have been shown in studies?

**Asthma**

Two main studies including over 1,500 adults and adolescents with inadequately controlled asthma showed that Tezspire was effective in reducing the number of severe asthma flareups.

In the first study, patients given Tezspire had on average 0.93 asthma flareups per year after one year of treatment compared with 2.10 in patients given placebo (a dummy treatment). In the second study, patients taking Tezspire had an average of 0.20 flareups per year after one year, compared with 0.72 in patients who received placebo.

**Chronic rhinosinusitis with nasal polyps**

A main study involving 410 adults with chronic rhinosinusitis with nasal polyps showed that Tezspire was more effective than placebo at reducing the size of the polyps and improving symptoms of the condition. The main measures of effectiveness were the nasal polyp score, which measures the size of polyps (each nostril is rated from 0, no polyps, to 4, complete blockage), as well as the average change in patient's nasal congestion score. The nasal congestion score assesses how symptoms impact daily life; scores range from 0 (no symptoms) to 3 (severe congestion). After 1 year of treatment, adults given Tezspire had an average reduction of around 2.5 in their nasal polyp score compared with an average reduction of around 0.4 for those given placebo. After 1 year of treatment, adults given Tezspire had an average reduction of around 1.7 in their nasal congestion score compared with an average reduction of around 0.7 for those given placebo.

## What are the risks associated with Tezspire?

For the full list of side effects and restrictions with Tezspire, see the package leaflet.

The most common side effects with Tezspire (which may affect up to 1 in 10 people) when used for the treatment of asthma include arthralgia (joint pain) and pharyngitis (sore throat). The most common side effect with Tezspire (which may affect up to 1 in 10 people) when used for the treatment of chronic rhinosinusitis is pharyngitis (sore throat).

## Why is Tezspire authorised in the EU?

The Agency considered that Tezspire was effective at reducing severe asthma flareups and improving symptoms of chronic rhinosinusitis with nasal polyps, as well as the size of the polyps. Regarding safety, side effects related to Tezspire were considered manageable.

The European Medicines Agency therefore decided that Tezspire's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Tezspire?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tezspire have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tezspire are continuously monitored. Suspected side effects reported with Tezspire are carefully evaluated and any necessary action taken to protect patients.

## Other information about Tezspire

Tezspire received a marketing authorisation valid throughout the EU on 19 September 2022.

Tezspire : EPAR - Medicine overview

Reference Number: EMADOC-1829012207-31788

English (EN) (146.75 KB - PDF)

**First published:** 21/09/2022

**Last updated:** 04/11/2025

[View](/en/documents/overview/tezspire-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-532)

български (BG) (171.15 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/bg/documents/overview/tezspire-epar-medicine-overview_bg.pdf)

español (ES) (146.47 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/es/documents/overview/tezspire-epar-medicine-overview_es.pdf)

čeština (CS) (168.65 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/cs/documents/overview/tezspire-epar-medicine-overview_cs.pdf)

dansk (DA) (146.1 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/da/documents/overview/tezspire-epar-medicine-overview_da.pdf)

Deutsch (DE) (149.72 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/de/documents/overview/tezspire-epar-medicine-overview_de.pdf)

eesti keel (ET) (144.5 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/et/documents/overview/tezspire-epar-medicine-overview_et.pdf)

ελληνικά (EL) (170.96 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/el/documents/overview/tezspire-epar-medicine-overview_el.pdf)

français (FR) (148.9 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/fr/documents/overview/tezspire-epar-medicine-overview_fr.pdf)

hrvatski (HR) (167.65 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/hr/documents/overview/tezspire-epar-medicine-overview_hr.pdf)

italiano (IT) (145.37 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/it/documents/overview/tezspire-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (177.41 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/lv/documents/overview/tezspire-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (168.44 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/lt/documents/overview/tezspire-epar-medicine-overview_lt.pdf)

magyar (HU) (168.52 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/hu/documents/overview/tezspire-epar-medicine-overview_hu.pdf)

Malti (MT) (172 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/mt/documents/overview/tezspire-epar-medicine-overview_mt.pdf)

Nederlands (NL) (145.96 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/nl/documents/overview/tezspire-epar-medicine-overview_nl.pdf)

polski (PL) (171.47 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/pl/documents/overview/tezspire-epar-medicine-overview_pl.pdf)

português (PT) (147.06 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/pt/documents/overview/tezspire-epar-medicine-overview_pt.pdf)

română (RO) (166.77 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/ro/documents/overview/tezspire-epar-medicine-overview_ro.pdf)

slovenčina (SK) (167.57 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/sk/documents/overview/tezspire-epar-medicine-overview_sk.pdf)

slovenščina (SL) (166.79 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/sl/documents/overview/tezspire-epar-medicine-overview_sl.pdf)

Suomi (FI) (145.19 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/fi/documents/overview/tezspire-epar-medicine-overview_fi.pdf)

svenska (SV) (145.16 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

04/11/2025

[View](/sv/documents/overview/tezspire-epar-medicine-overview_sv.pdf)

Tezspire : EPAR - Risk management plan

English (EN) (974.18 KB - PDF)

**First published:** 21/09/2022

**Last updated:** 22/10/2025

[View](/en/documents/rmp/tezspire-epar-risk-management-plan_en.pdf)

## Product information

Tezspire : EPAR - Product Information

English (EN) (2.9 MB - PDF)

**First published:** 21/09/2022

**Last updated:** 22/10/2025

[View](/en/documents/product-information/tezspire-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-195)

български (BG) (1.21 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/bg/documents/product-information/tezspire-epar-product-information_bg.pdf)

español (ES) (1.12 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/es/documents/product-information/tezspire-epar-product-information_es.pdf)

čeština (CS) (3.85 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/cs/documents/product-information/tezspire-epar-product-information_cs.pdf)

dansk (DA) (1.11 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/da/documents/product-information/tezspire-epar-product-information_da.pdf)

Deutsch (DE) (1.16 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/de/documents/product-information/tezspire-epar-product-information_de.pdf)

eesti keel (ET) (992.51 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/et/documents/product-information/tezspire-epar-product-information_et.pdf)

ελληνικά (EL) (1.07 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/el/documents/product-information/tezspire-epar-product-information_el.pdf)

français (FR) (1.18 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/fr/documents/product-information/tezspire-epar-product-information_fr.pdf)

hrvatski (HR) (1.1 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/hr/documents/product-information/tezspire-epar-product-information_hr.pdf)

íslenska (IS) (1.03 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/is/documents/product-information/tezspire-epar-product-information_is.pdf)

italiano (IT) (1.06 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/it/documents/product-information/tezspire-epar-product-information_it.pdf)

latviešu valoda (LV) (1.12 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/lv/documents/product-information/tezspire-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.05 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/lt/documents/product-information/tezspire-epar-product-information_lt.pdf)

magyar (HU) (1.22 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/hu/documents/product-information/tezspire-epar-product-information_hu.pdf)

Malti (MT) (1.18 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/mt/documents/product-information/tezspire-epar-product-information_mt.pdf)

Nederlands (NL) (1.04 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/nl/documents/product-information/tezspire-epar-product-information_nl.pdf)

norsk (NO) (1.05 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/no/documents/product-information/tezspire-epar-product-information_no.pdf)

polski (PL) (1.15 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/pl/documents/product-information/tezspire-epar-product-information_pl.pdf)

português (PT) (1.05 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/pt/documents/product-information/tezspire-epar-product-information_pt.pdf)

română (RO) (1.08 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/ro/documents/product-information/tezspire-epar-product-information_ro.pdf)

slovenčina (SK) (1.01 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/sk/documents/product-information/tezspire-epar-product-information_sk.pdf)

slovenščina (SL) (1.15 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/sl/documents/product-information/tezspire-epar-product-information_sl.pdf)

Suomi (FI) (1.05 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/fi/documents/product-information/tezspire-epar-product-information_fi.pdf)

svenska (SV) (1.03 MB - PDF)

**First published:**

21/09/2022

**Last updated:**

22/10/2025

[View](/sv/documents/product-information/tezspire-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000245013 20/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tezspire : EPAR - All Authorised presentations

English (EN) (40.64 KB - PDF)

**First published:** 21/09/2022

**Last updated:** 19/04/2023

[View](/en/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-533)

български (BG) (34.28 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/bg/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_bg.pdf)

español (ES) (32.01 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/es/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_es.pdf)

čeština (CS) (32.95 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/cs/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (33.67 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/da/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (33.92 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/de/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (30.68 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/et/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (32.73 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/el/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_el.pdf)

français (FR) (31.61 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/fr/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (39.05 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/hr/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (32.28 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/is/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_is.pdf)

italiano (IT) (44.59 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/it/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (32.24 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/lv/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (32.27 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/lt/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (33.69 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/hu/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (41.68 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/mt/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (32.32 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/nl/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (33.51 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/no/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_no.pdf)

polski (PL) (41.33 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/pl/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_pl.pdf)

português (PT) (33.28 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/pt/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_pt.pdf)

română (RO) (31.73 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/ro/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (33.18 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/sk/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (30.84 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/sl/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (30.84 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/fi/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (32.28 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

19/04/2023

[View](/sv/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tezspire Active substance tezepelumab International non-proprietary name (INN) or common name tezepelumab Therapeutic area (MeSH)

- Asthma
- Sinusitis

Anatomical therapeutic chemical (ATC) code R03DX11

### Pharmacotherapeutic group

Drugs for obstructive airway diseases

### Therapeutic indication

Asthma Tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Chronic rhinosinusitis with nasal polyps (CRSwNP) Tezspire is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids, and/or surgery do not provide adequate disease control.

## Authorisation details

EMA product number EMEA/H/C/005588

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

AstraZeneca AB

151 85 Sodertalje

Opinion adopted 21/07/2022 Marketing authorisation issued 19/09/2022 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tezspire : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (161.25 KB - PDF)

**First published:** 21/07/2025

**Last updated:** 22/10/2025

[View](/en/documents/procedural-steps-after/tezspire-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tezspire : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (171.49 KB - PDF)

**First published:** 09/11/2022

**Last updated:** 21/07/2025

[View](/en/documents/procedural-steps-after/tezspire-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Tezspire-H-C-005588-EMAVR0000245013 : EPAR - Assessment report - Variation

Reference Number: EMADOC-1700519818-2093764

English (EN) (3.95 MB - PDF)

**First published:** 22/10/2025

[View](/en/documents/variation-report/tezspire-h-c-005588-emavr0000245013-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Tezspire

Adopted

Reference Number: EMADOC-1700519818-2094000

English (EN) (124.63 KB - PDF)

**First published:** 19/09/2025

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tezspire_en.pdf)

Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/422404/2023

English (EN) (116.67 KB - PDF)

**First published:** 22/09/2023

[View](/en/documents/scientific-conclusion/scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Tezspire-H-C-005588-P46-008 : EPAR - Assessment report

Adopted

Reference Number: EMA/273154/2023

English (EN) (1.44 MB - PDF)

**First published:** 10/08/2023

[View](/en/documents/variation-report/tezspire-h-c-005588-p46-008-epar-assessment-report_en.pdf)

Tezspire-H-C-5588-P46-007 : EPAR - Assessment report

Adopted

Reference Number: EMA/242279/2023

English (EN) (3.91 MB - PDF)

**First published:** 05/06/2023

[View](/en/documents/variation-report/tezspire-h-c-5588-p46-007-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Tezspire : EPAR - Public assessment report

Adopted

Reference Number: EMA/682391/2022

English (EN) (9.61 MB - PDF)

**First published:** 21/09/2022

**Last updated:** 18/09/2025

[View](/en/documents/assessment-report/tezspire-epar-public-assessment-report_en.pdf)

#### News on Tezspire

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 September 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-september-2025) 19/09/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022) 22/07/2022

#### More information on Tezspire

- [EMEA-001613-PIP03-21-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001613-pip03-21-m01)
- [Impact of biologics on inhaled corticosteroids reduction (MOON LIGHT) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000855)
- [Sustainability of response to biologics in severe asthma and predictors of late failure among patients in an international registry (SHINE) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000788)
- [An Observational Multi-Country Post-Authorisation Safety Study to Evaluate the Risk of Serious Adverse Cardiovascular Events in Adolescent and Adult Patients with Severe Asthma taking Tezepelumab (TRESPASS) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000169)
- [Assessing the impact of remission at 12-months post-initiation of biologic therapy on long-term clinical outcomes of patients with severe asthma (SPOTLIGHT) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000789)
- [CROSSROADS-2: Clinical Characteristics, Treatment Patterns, and Treatment Outcomes Among Users of Tezspire: An Electronic Medical Record (EMR) study (20220066) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000053)
- [Assessing the impact of earlier access to biologics on remission and natural course of asthma (GLEAM) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000530)
- [Real-World Analysis of Exacerbations and Exacerbation-Related Costs Among Patients with Asthma Receiving Tezepelumab (CROSSROADS-5) (20240066) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000514)
- [A Non-Interventional Multi-Database Post-Authorisation Study to Assess Pregnancy-Related Safety Data from Women with Severe Asthma Exposed to Tezepelumab (TREATY) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000176)
- [CROSSROADS-1: Treatment Outcomes among Tezspire Users: A Claims Data Study (20230159) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000062)

**This page was last updated on** 22/10/2025

## Share this page

[Back to top](#main-content)